Stryker Hits 52-Week Low After Missing Q1 Profit and Revenue Estimates

Key Facts

Stryker (SYK) reported disappointing Q1 results, missing Wall Street estimates for both profit and revenue, which sent its stock price to a new 52-week low. The company posted earnings per share of $2.60 on revenue of $6.02 billion, both falling short of analyst expectations. This underperformance was primarily driven by softer demand for spinal and orthopedic surgery devices, a key segment for the medical technology firm. Despite these headwinds and a cyberattack in early March, Stryker maintained its full-year financial guidance. Additionally, the company announced a definitive agreement to acquire Amplitude Vascular Systems to bolster its portfolio. Investors remain focused on margin pressures within the MedTech sector and the ongoing technical weakness impacting peers like DexCom.

Version History